Nano-X Imaging Ltd（NNOX）财务数据NNOXNano-X Imaging Ltd

Nano-X Imaging Ltd (NNOX) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is Radiology Service, accounting for 89.6% of total sales, equivalent to $2.72M. Other significant revenue streams include Nanox ARC and AI Solutions. Understanding this composition is critical for investors evaluating how NNOX navigates market cycles within the Advanced Medical Equipment & Technology industry.

Evaluating the bottom line, Nano-X Imaging Ltd maintains a gross margin of -71.68%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -355.32%, while the net margin is -1335.11%. These profitability ratios, combined with a Return on Equity (ROE) of -98.98%, provide a clear picture of how effectively NNOX converts its operational activities into shareholder value.

In the context of the broader market, NNOX competes directly with industry leaders such as MLSS and XTLB. With a market capitalization of $18.70M, it holds a significant position in the sector. When comparing efficiency, NNOX's gross margin of -71.68% stands against MLSS's 66.55% and XTLB's N/A. Such benchmarking helps identify whether Nano-X Imaging Ltd is trading at a premium or discount relative to its financial performance.

The company reported a Q2 2026 net loss of $55.5 million, significantly worse than previous quarters, and a gross margin of -71.68%. Revenue growth of 37% year-over-year is overshadowed by these losses.